Immutep Announces Positive Update on IMP761 Phase I Study

Immutep Limited has announced a positive update on its Phase I study of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The single-ascending dose portion of the study has successfully completed 2.5 and 7 mg/kg dosing levels. The study observed a dose-dependent immunosuppressive effect against a foreign antigen with a favorable safety profile. A significant reduction in T cell activity was noted, indicating IMP761's potential efficacy in treating autoimmune diseases. The trial will continue as planned, with further updates anticipated in the first half of 2026, including a potential presentation at a major medical conference. IMP761 is designed to silence dysregulated T cells, addressing the root cause of autoimmune diseases by enhancing the "brake" function of LAG-3.